

P	Gender	Age at IR	Nº of cycle	IR Characteristics	Anaphylaxis grade	Protocol, target dose (mg)	Nº of DP	Description of DZT-related adverse events	Protocol adaptation	Protocol suspension
1	F	3	U	Lip and orbital Ao and paraesthesia of the feet	Isolated MC symptoms	Confino-Cohen, 354	2	Lip Ao	No	No
2	M	9	8	Lip Ao, plantar itch, dysphagia and dyspnoea	Moderate	Confino-Cohen, 700	4	Generalized erythema, lip Ao, odynophagia, nasal pruritus, stridor and abdominal pain	Yes	No
3	M	7	10	Lip Ao, facial flushing and dysphonia	Moderate	Confino-Cohen, 440	14	Absent	No	No
4	F	3	7	Facial Ao and generalized erythema	Isolated MC symptoms	Confino-Cohen, 467	8	Facial flushing and lip Ao	No	No
5	F	3	8	Generalized erythema and orbital Ao	Isolated MC symptoms	Castells, 473	4	Ao and flush of the face and desaturation with labial cyanosis	Yes	No
6	M	2	6	Generalized erythema	Isolated MC symptoms	Castells, 500	9	Absent	No	No
7	M	9	8	Face and trunk erythema, sneezing, cough, dyspnoea and abdominal pain	Moderate	Castells, 706	6	Generalized erythema and tachypnea		No
8	F	7	10	Generalized erythema, ocular congestion, cough, dyspnoea, stridor, desaturation with labial cyanosis and vomiting	Severe	Castells, 500	6	Generalized pruritus, facial Ao and abdominal pain	Yes	No
9	M	3	7	Generalized erythema and orbital Ao	Isolated MC symptoms	Castells, 346	3	Generalized erythema, palmoplantar pruritus, odynophagia and abdominal pain	Yes	Yes
10	F	3	8	Generalized erythema	Moderate	Castells, 435	6	Nose and ear redness and fever	No	No
11	F	1	9	Facial and trunk erythema and fever	Moderate	Castells, 279	3	U	Yes	Yes
12	F	4	10	Facial and trunk maculopapular exanthema and cough	Moderate	Castells, 374	6	Face erythema, orbital Ao and crying hoarseness	Yes	No
13	M	2	6	Face erythema and Ao oropharyngeal pruritus and cough	Moderate	Castells, 550	11	Generalized erythema and nausea	No	No
14	M	4	8	Face erythema, ear Ao, odynophagia, cough, bronchospasm, stridor and desaturation with labial cyanosis	Severe	Castells, 396	11	Generalized erythema, cough, bronchospasm, vomiting and prostration	Yes	No
15	F	4	2	Face and trunk maculopapular exanthema	Isolated MC symptoms	Castells, 327	7	Generalized pruritic exanthema	Yes	No

Ao, Angioedema; DP, Desensitization procedures; F, Female; IR, Initial reaction; M, male; MC, Mucocutaneous; P, Patient, U, Unknown

Only patient 3 had been previously exposed to the drug 5 years earlier, as the HSR occurred during a new treatment after disease progression

Patients 6,7,12 and 14 were atopic

Only patient 2 was treated with epinephrine at the IR

Skin tests were performed in patients 1,2,3 and 5. Only patient 5 had positive intradermal test.

Specific IgE to carboplatin and to cisplatin were evaluated in patients 2,3 and 5 and were positive only in patient 5 (carboplatin: 1.6 kU/L and cisplatin: 4.2 kU/L, UniCAP; Pharmacia, Uppsala, Sweden)

Severity of anaphylaxis was classified according to the criteria for the management of anaphylaxis in childhood. [1]

After carboplatin discontinuation, vinblastine was prescribed in patient 11 and cyclophosphamide in patient 11.

1. Muraro, A., et al., *The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology*. Allergy, 2007. **62**(8): p. 857-71.